Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139598

Published: 2020

Journal Articles

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Sandra Cohen, MD FRCP(C), Jean Roy, MD, Jean-Sébastien Delisle, MD PhD, Nadia M. Bambace, MD, Imran Ahmad, MD, Silvy Lachance, MD FRCP, Léa Bernard, MD, Frederic Barabe, MD, Thomas L. Kiss, MD, Lambert Busque, MD, Denis-Claude Roy, MD, Filippo Milano, MD PhD, Guy Sauvageau, MD PhD

Blood (2019) 134 (Supplement_1): 3245.

https://doi.org/10.1182/blood-2019-121698

Published: 2019

Journal Articles

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Blood (2018) 132 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2018-99-110188

Published: 2018

Journal Articles

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Richard Leblanc, MD FRCPC, Imran Ahmad, MD MPH, Rafik Terra, PhD, Séverine Landais, PhD, Céline Nkoue, MD, Michael Sebag, MD PhD, Émilie Lemieux Blanchard, MD FRCPC, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD, Thomas L. Kiss, MD, Silvy Lachance, MD FRCP, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD

Blood (2018) 132 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2018-99-112313

Published: 2018

Journal Articles

Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality

Sandra Cohen, MD, Jean Roy, MD, Silvy Lachance, MDFRCPC, Anne Marinier, PhD, Denis-Claude Roy, MD, Jean-Sébastien Delisle, MD PhD, Lambert Busque, MD, Pierre Caudrelier, MD, Fannie Larochelle, Philippe Bouchard, BPharm, Jean Roy, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Thomas L Kiss, MD, Sébastien Lemieux, PhD, Peter W. Zandstra, PhD, Guy Sauvageau, MD, PhD

Blood (2017) 130 (Supplement 1): 658.

https://doi.org/10.1182/blood.V130.Suppl_1.658.658

Published: 2017

Journal Articles

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Josie-Anne Boisjoly, MD, Philippe Bouchard, BPharm, Sandra Cohen, MD FRCP(C), Imran Ahmad, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Jean-Sébastien Delisle, MD PhD, Thomas L Kiss, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD, Silvy Lachance, MDFRCPC

Blood (2017) 130 (Supplement 1): 2022.

https://doi.org/10.1182/blood.V130.Suppl_1.2022.2022

Published: 2017

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Richard LeBlanc, MDFRCPC, Imran Ahmad, MD M.Sc., Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD, Jean-Sébastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MDFRCPC, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2017) 130 (Supplement 1): 4556.

https://doi.org/10.1182/blood.V130.Suppl_1.4556.4556

Published: 2017

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Richard LeBlanc, MD, Imran Ahmad, MD, Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Sandra Cohen, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2016) 128 (22): 2306.

https://doi.org/10.1182/blood.V128.22.2306.2306

Published: 2016

Journal Articles

Evaluation of the Impact of Hematopoietic Stem Cell Transplant on the Quality of Life of Elderly Patients Treated for Lymphoma

Christopher Lemieux, MD, Nadia M. Bambace, MD, Jean Roy, MD, Sandra Cohen, MD, Imran Ahmad, MD, Lea Bernard, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MD

Blood (2016) 128 (22): 4788.

https://doi.org/10.1182/blood.V128.22.4788.4788

Published: 2016

Journal Articles

Tandem Autologous Followed By Nonmyeloablative Allogeneic Transplantation in Relapsed High Risk Follicular Lymphoma Leads to Excellent Long Term Progression-Free Survival after 8 Years of Follow-up

Magalie Tardif, MSc, MD Student, Imran Ahmad, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Lambert Busque, MD PhD FRCPC, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Isabelle Fleury, MD, Silvy Lachance, MD, Luigina Mollica, MD PhD, Céline Nkoué, MD, Denis-Claude Roy, MD, Jean Roy, MD, Sandra Cohen, MD

Blood (2016) 128 (22): 4677.

https://doi.org/10.1182/blood.V128.22.4677.4677

Published: 2016

Journal Articles

Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Elderly Patients with Lymphoma: Chemosensitive Disease Rather Than Age or Co-Morbidity Index Predicts Outcome

Christopher Lemieux, MD, Imran Ahmad, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Sandra Cohen, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Jean Roy, MD PhD, Silvy Lachance, MD

Blood (2015) 126 (23): 3171.

https://doi.org/10.1182/blood.V126.23.3171.3171

Published: 2015

Journal Articles

Pre-Transplant Remission Status and Peripheral Blood Stem Cell Graft Contribute To Long-Term Outcome After Myeloablative Sibling-Donor Allogeneic Transplant For Multiple Myeloma

Imran Ahmad, MD, MSc, Sandra Cohen, MD, Silvy Lachance, MD, Guy Sauvageau, MD, PhD, Denis-Claude Roy, MD, Lambert Busque, MD, Thomas Kiss, MD, Jean-Sebastien Delisle, MD, PhD, Lea Bernard, MD, Richard LeBlanc, MD, Jean Roy, MD

Blood (2013) 122 (21): 5541.

https://doi.org/10.1182/blood.V122.21.5541.5541

Published: 2013

Journal Articles

High Progression-Free Survival At 10 Years After Tandem Autologous/Nonmyeloablative Allogeneic Transplants For Multiple Myeloma In a Cohort Of 93 Patients: Impact Of Disease Remission Status At Transplant and Chronic Graft-Versus-Host Disease

Imran Ahmad, MD, MSc, Sandra Cohen, MD, Silvy Lachance, MD, Guy Sauvageau, MD, PhD, Thomas Kiss, MD, Lambert Busque, MD, Denis-Claude Roy, MD, Jean-Sebastien Delisle, MD, PhD, Lea Bernard, MD, Richard LeBlanc, MD, Jean Roy, MD

Blood (2013) 122 (21): 3353.

https://doi.org/10.1182/blood.V122.21.3353.3353

Published: 2013

Journal Articles

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Blood (2013) 122 (21): 368.

https://doi.org/10.1182/blood.V122.21.368.368

Published: 2013

NARROW

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Evaluation of the Impact of Hematopoietic Stem Cell Transplant on the Quality of Life of Elderly Patients Treated for Lymphoma

Tandem Autologous Followed By Nonmyeloablative Allogeneic Transplantation in Relapsed High Risk Follicular Lymphoma Leads to Excellent Long Term Progression-Free Survival after 8 Years of Follow-up

Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Elderly Patients with Lymphoma: Chemosensitive Disease Rather Than Age or Co-Morbidity Index Predicts Outcome

Pre-Transplant Remission Status and Peripheral Blood Stem Cell Graft Contribute To Long-Term Outcome After Myeloablative Sibling-Donor Allogeneic Transplant For Multiple Myeloma

High Progression-Free Survival At 10 Years After Tandem Autologous/Nonmyeloablative Allogeneic Transplants For Multiple Myeloma In a Cohort Of 93 Patients: Impact Of Disease Remission Status At Transplant and Chronic Graft-Versus-Host Disease

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only